Introduction
National Kidney Foundation -The American Kidney Foundation (NKF, 2002) defines the chronic renal failure as kidney damage lasting more than 3 months, caused by structural or functional disorders of the kidneys, with or without a fall in the volume of glomerular filtration rate (GFR), which is manifested by histological abnormalities or disorders in the characteristics of blood, urine or the appearance of kidney with a decrease in glomerular filtration rate (GFR) <60 ml/min/1.73m 2 , which lasts more than 3 months, with or without renal failure (1, 2) .
Chronic renal failure (CRF) is a gradual, progressive and irreversible deterioration of kidney function, a toxic syndrome caused by decreased glomerular filtration due to the deterioration of functional nephrons. It is characterized by varying degrees of azotemia, but also by changes in volume and composition of body fluids and electrolyte imbalance, and many hormones.
Very early in the progression of CRF there occur disturbances in the metabolism of calcium (Ca) and phosphorus (P), i.e. parathyroid hormone (PTH) and vitamin D3, according to some authors, at glomerularae filtration rate (GFR) of 60ml/min/1,73m 2 , that is, in the second stage of CRF. From stage to stage, this disorder is getting www.medfak.ni.ac.rs/amm worse, considerably affecting the patients on dialysis.
Complex causal relationships in the electrolyte-hormone imbalance can be explained by the decline in kidney tissue and leads to reduced synthesis of the active metabolite of vitamin D3 (1,25 (ON) 2D3), which leads to reduced absorption of Ca at the level of interstitial and hypocalcemia. Hypocalcemia leads to increased stimulation of parathyroid glands and develops the state of secondary hyperparathyroidism, or there are changes in normal Ca-regulation of PTH secretion (impaired "set point" for Ca 2+). It also leads to phosphate retention in the kidney and hyperphosphataemia. If we add the effect of bone resistance to PTH, it can be concluded that this metabolic imbalance leads to significant disturbances in bone meta'-bolism, especially in patients on dialysis (3) (4) (5) (6) .
Progressive bone abnormalities in patients with CRF is traditionally referred to as renal osteodystrophy (ROD). However, the American Kidney Foundation (National Kidney Foundation-NKF, 2007) approved a new recommendation on which the term ROD used to explain the change of the bone morphology in patients with CRF, based solely on the histological results obtained by bone biopsy. Clinical, biochemical and radiological abnormalities, which reflect the ROD, would be treated as elements of a broader clinical syndrome, a disorder of bone mineral metabolism in CKD (Chronic Kidney Disease-Mineral and Bone Disorder; CKD-MBD Syndrome). CKD-MBD syndrome is characterized by one of the following events:
-Abnormalities in the metabolism of Ca, P, PTH and vitamine D3 -Abnormalities of bone turnover, mineralization, volume, and bone growth -Vascular calcification or calcification of other soft tissues (7) .
Many authors believe that the bone biopsy is "gold" standard in the diagnosis and monitoring of bone abnormalities (8) , but bearing in mind invasiveness of a procedure, the American Kidney Foundation (National Kidney Foundation) recommends that a bone biopsy should be performed only in clinical-biochemically unclear cases ( eg. in patients with high levels of PTH and low serum alkaline phosphatase) (9) .
Clinical symptoms of bone and mineral metabolism occur quite late in the CRF. Some studies suggest that the clinical symptoms are present in less than 10% of patients and that histomorhological changes present in 35-90% of cases (10) . Given that disturbance of mineral bone metabolism can be laboratory diagnosed before the onset of symptoms, it is important to monitor the levels, above all, of parathyroid hormone and alkaline phosphatase, Ca, P and vitamin D in order to timely apply an adequate therapy and avoid more difficult consequences.
It is certain that the extended, multi-year treatment of patients on hemodialysis can only worsen this problem, if not timely detected and properly treated. Given the chronic problems with the metabolism of calcium and phosphorus in patients on HD, we were interested to isolate the most important parameters which, during the time spent on HD, could influence bone disease in these patients.
Aim
The aim of this study was the assessment of the influence of peritoneal dialysis treatment on biochemical parameters of mineral and bone metabolism in hemodialysis patients as well as the allocation of the most important parameters to monitor this condition in these patients.
Methods
The study was conducted at the Department of Nephrology, Clinical Center Niš, January, 2009.
By type of clinical research, this study is among the epidemiological studies and behavioral studies, and according to the organization of clinical research, this is an observational-retrospective study, complying with the principles of evidencebased medicine.
The target group of this survey was the one involving patients on chronic hemodialysis, whose urine output decreased to 400 ml/24h. The study included 172 patients, 113 males and 59 females, mean age of 58.69 years.
Patients were divided into groups based on the length of peritoneal dialysis treatment:
I group -peritoneal dialysis treatment length less than 5 years;
II group -peritoneal dialysis treatment length from 5 to 10 years; III group -peritoneal dialysis treatment length over 10 years.
In our patients we determined the following parameters: concentration of total serum calcium, serum phosphate, alkaline phosphatase, and aluminum in serum -all determined in the laboratory of the Clinic of Nephrology, Clinical Center Niš. Analyses were performed by routine biochemical methods in an automatic analyzer A25 Company Bio Systems. Determination of intact PTH was performed in the laboratory of the Centre for Nuclear Medicine, Clinical Center Niš, imunoradiometric analysis (IRMA) on LKB gamma counter.
The reference range was set according to the Recommendations of Good Practice of the American Initiative for successful outcome of dialysis (K / DOQI Clinical Practice Guidelines) for the PTH of 150-400 pg / ml, calcium from 2.10 -2.60 mmol / 1, for phosphorus of 1.13-1.78 mmol/l and the product Ca x P <4:40 mmol 2 /l 2 , [11, 12] . Statistical analysis was done with SSPS 16.0 statistical package (13) . For age distribution, we used the arithmetic mean and standard deviation. To display the significance of differences between the studied characteristics of patients by age group, we used T-test and Pearson's linear correlation test. 
Results

Discussion
Abnormalities of mineral and bone metabolism are frequent in patients both with predialysis chronic renal insufficiency and patients on dialysis. An effective clinical approach to these patients includes the control of phosphate retention and prevention of hyperphosphataemia, maintaining the serum Ca concentrations in normal concentrations and prevention of proliferation of parathyroid gland and significant increase in PTH (14) .
The present study included 172 patients, 113 male patients (65.70%) and 59 females, mean age 58.69±12:54 years (Table 1 ). This trend of age and sex distribution remains by the investigated groups (Tables 2 and 4) .
The most common underlying disease in the group of examinees was chronic glomerulonephritis (20) , the condition after nephrectomy (11) and chronic pyelonephritis (11) . There were 11 diabetics in total. However, in most patients, 85 of them, primary renal disease is not known ( Table 3) .
The majority of patients have been dialysed less than 5 years, 39.54%, a slightly smaller percentage of 5 to 10 years -34.20% of them. However, the number of patients (26.16%) on dialysis for more than 10 years is not negligible ( Table 2) .
The lowest dose of dialysis 2.73±0.44 is reported in patients during the first 5 years of dialysis; somewhat higher dose of 2.98±0.13 is applied in patients who are up to 10 years on peritoneal dialysis treatment; standard three hemodialyses for 4 hours a week are given to all patients with more than 10 years of dialysis treatment (Table 4) .
Examined parameters of bone metabolism showed the following characteristics in our respondents (Tables 4 and 5) .
Phosphorus, as the most important parameter of mineral bone metabolism control was increased in all our patients, with rising of values along with the duration of dialysis (Group I: 1.77±0.58; II: 1.97±0.66, III: 1.92±0.82); statistical differences were not found among the four groups (p>0.05).
Calcemia values were also on the rise with duration of dialysis, but, unlike phosphorus, statistically significantly higher (I:II 2.21±0.31/ 2.50±0.33, p<0.0001; I:III 2.21±0.31/2.53±0.32, p<0.0001), so that the proportion increased as well as the value of products CaxP after 5 years of dialysis (group II patients, p=0.002). The increase in product CaxP was maintained (III, p=0.01) and, above all, on the account of the increased value of calcemia.
Similar results to the values of calcemia were obtained for alkaline phosphatase (group: 105.12±65.60; II: 125.27±96.79, III: 172.43± 163.99), with significantly higher values of AF for group III (p<0.05 ).
Although PTH showed the rising trend during the time spent on dialysis treatment (PTH for the first group: 234.21±18.74; II: 273.09±247.98; III: 489.46±468.49;) higher values of PTH were found only for group III patients (p<0001).
In respect to the analyzed groups, patients in group I had higher values of phosphorus and lower values of calcemia and moderately elevated serum PTH and AF in 63% of cases, which best suits the bone disease with rapid turnover (Table 5) . Although all our patients were treated with trusses calcium phosphate-based, a satisfactory control of phosphorus during their stay on HD was not achieved. The reasons may be numerous, but most are inadequate intake of phosphorus through diet and irregular intake of phosphorus trusses.
In our study, after five years of dialysis, we observed a significant increase in calcemia in relation to phosphorus, alkaline phosphatase, and PTH (Table 5 ). These findings support further deterioration of bone diseases, development of mixed forms and adynamic bone disease. These disorders require a more complex approach to treatment and monitoring of bone disease on hemodialysis, and often, in addition to severe bone deformities, results in deterioration of cardiovascular morbidity and mortality in these patients (15) (16) (17) (18) .
Some studies suggest that bone-specific AF (BAF) shows a very large statistically significant correlation between the PTH in monitoring the progression of bone disease, whereas this correlation is not always present in the Ca-P-AF and AF. It is also stated that there is a statistically significant correlation between AF and total PTH, but to a lesser extent (19, 20) .
In our study, PTH showed a good correlation with alkaline phosphatase (r xy =0961, p=0.01) and calcium (r xy =0904, p=0.01) (Figure 1 ), but not with the product CaxP (r xy =0245, p=0.01). Alkaline phosphatase is also well-correlated with calcium (r xy =0.776, p=0.01) but not with the product CaxP (r xy =0256, p=0.01). However, the correlation of serum calcium and phosphorus was statistically insignificant (r xy =-0.105, p=0.01) (Figure 2 ), on the basis of which it follows that the most reliable marker for clinical monitoring of bone disease is PTH, which correlates well with the alkaline phosphatase and calcemia, while the values of calcium and phosphorus, especially phosphorus, varied.
Bearing in mind that mineral bone metabolism disorder leads to a significant deterio-ration in quality of life, morbidity and mortality, primarily by cardiovascular system, the Recommendations for Good Clinical Practice of the American Initiative for the Successful Outcome of Dialysis (K/DOQI Clinical Practice Guidelines) require that in patients on dialysis every three months the levels of PTH and AF be determined, as well as monthly levels of Ca and P in patients on therapy and more frequently, (21) to allow for adequate control, slow the progression and improve quality of life of patients on dialysis.
Conclusion
In our study we have shown that the duration of hemodialysis is correlated with significant metabolism disorders of calcium and phosphorus in hemodialysis patients. During the first 5 years of hemodialysis in the patients examined we noticed elevated values of serum phosphorus and low values of calcemia and moderately elevated serum PTH and AF in 63% of our patients, which corresponds to the bone disease with rapid turnover.
With further duration of dialysis, the values of calcemia significantly grow in relation to phosphorus, PTH and AF, which speaks in favor of development of other mixed forms of bone disease, and in some patients of development of adynamic bone disease.
By the investigation of biochemical markers of bone-mineral metabolism we have shown that PTH is the most reliable marker for clinical monitoring of bone disease, which correlates well with the alkaline phosphatase and calcemia, while the values of calcium and phosphorus, especially phosphorus vastly varied and were not reliable indicators of bone metabolism in hemodialysis patients.
Increased calcium and phosphorus product along with dialysis treatment leads to increased risk of intravascular calcifications and subsequent increase in cardiovascular morbidity and mortality in these patients.
